[1] Agostinis C, Balduit A, Mangogna A, et al.Immunological Basis of the Endometriosis: The Complement System as a Potential Therapeutic Target[J]. Front Immunol, 2021, 11: 599117.
[2] Hogg C, Horne AW, Greaves E.Endometriosis-Associated Macrophages: Origin, Phenotype, and Function[J]. Front Endocrinol (Lausanne), 2020, 11: 7.
[3] Agostinis C, Balduit A, Mangogna A, et al.Immunological Basis of the Endometriosis: The Complement System as a Potential Therapeutic Target[J]. Front Immunol, 2021, 11:599117.
[4] Wang Y, Nicholes K, Shih IM.The Origin and Pathogenesis of Endometriosis[J]. Annu Rev Pathol, 2020, 15: 71-95.
[5] Taylor HS, Kotlyar AM, Flores VA.Endometriosis is a chronic systemic disease: clinical challenges and novel innovations[J]. Lancet, 2021, 397(10276): 839-852.
[6] Zitvogel L, Kepp O, Galluzzi L, et al.Inflammasomes in carcinogenesis and anticancer immune responses[J]. Nat Immunol, 2012, 13(4): 343-351.
[7] Khan KN, Yamamoto K, Fujishita A, et al.Association between FOXP3+ regulatory T-cells and occurrence of peritoneal lesions in women with ovarian endometrioma and dermoid cysts[J]. Reprod Biomed Online, 2019, 38(6): 857-869.
[8] Josefowicz SZ, Lu LF, Rudensky AY.Regulatory T cells:mechanisms of differentiation and function[J]. Annu Rev Immunol, 2012, 30: 531-364.
[9] Wang D, Quiros J, Mahuron K, et al.Targeting EZH2 Reprograms Intratumoral Regulatory T Cells to Enhance Cancer Immunity[J]. Cell Rep, 2018, 23(11): 3262-3274.
[10] Wang J, Gong R, Zhao C, et al.Human FOXP3 and tumour microenvironment[J]. Immunology, 2023,168(2): 248-255.
[11] Kawakami, Kitagawa Y, Chen KY, et al. Distinct Foxp3 enhancer elements coordinate development, maintenance, and function of regulatory T cells[J]. Immunity, 2021, 54(5):947-961.
[12] Jia H, Qi H, Gong Z, et al.The expression of FOXP3 and its role in human cancers[J]. Biochim Biophys Acta Rev Cancer, 2019, 1871(1): 170-178.
[13] Králíčková M, Vetvicka V.Immunological aspects of endometriosis: a review[J]. Ann Transl Med, 2015, 3(11): 153.
[14] Yang X, Wang W, Xu J, et al.Significant association of CD4+CD25+Foxp3+ regulatory T cells with clinical findings in patients with systemic lupus erythematosus[J]. Ann Transl Med, 2019, 7(5): 93.
[15] Yang X, Lun Y, Jiang H, et al.SIRT1-Regulated Abnormal Acetylation of FOXP3 Induces Regulatory T-Cell Function Defect in Hashimoto's Thyroiditis[J]. Thyroid, 2018, 28(2): 246-256.
[16] Su Q, Jing J, Li W, et al.Impaired Tip60-mediated Foxp3 acetylation attenuates regulatory T cell development in rheumatoid arthritis[J]. J Autoimmun, 2019, 100: 27-39.
[17] Kahraman DS, Diniz G,Sayhan S, et al.The prognostic significance of pdl1 and foxp3 expressions in tumor cells and the tumor microenvironment of ovarian epithelial tumors[J]. Int J Clin Exp Pathol, 2018, 11(8): 3884-3890.
[18] Zhao M, Li Y, Wei X, et al.Negative immune factors might predominate local tumor immune status and promote carcinogenesis in cervical carcinoma[J]. Virol J, 2017, 14(1): 5.
[19] 张雅丽,侯安丽,王杏茶,等. CD4+CD25+Foxp3+调节性T细胞在子宫内膜癌患者外周血中的表达及意义[J]. 现代免疫学,2015,35(5):410-414.
[20] Hogg C, Horne AW, Greaves E.Endometriosis-Associated Macrophages: Origin, Phenotype, and Function[J]. Front Endocrinol (Lausanne), 2020, 11: 17.
[21] Olkowska-Truchanowicz J, Sztokfisz-Ignasiak A, Zwierzchowska A, et al.Endometriotic Peritoneal Fluid Stimulates Recruitment of CD4+CD25highFOXP3+ Treg Cells[J]. J Clin Med, 2021, 10(17): 3789.
[22] Berbic M, Hey-Cunningham AJ, Ng C, et al.The role of Foxp3+ regulatory T-cells in endometriosis: a potential controlling mechanism for a complex, chronic immunological condition[J]. Hum Reprod, 2010, 25(4): 900-907.
[23] Riccio LDGC, Santulli P, Marcellin L, et al.Immunology of endometriosis[J]. Best Pract Res Clin Obstet Gynaecol, 2018, 50: 39-49.
[24] Helfen A, Roth J, Ng T, et al.In Vivo Imaging of Pro- and Antitumoral Cellular Components of the Tumor Microenvironment[J]. J Nucl Med, 2018, 59(2): 183-188.
[25] Lu L, Barbi J, Pan F.The regulation of immune tolerance by FOXP3[J]. Nat Rev Immunol, 2017, 17(11): 703-717.
[26] Khan KN, Yamamoto K, Fujishita A, et al.Association between FOXP3+ regulatory T-cells and occurrence of peritoneal lesions in women with ovarian endometrioma and dermoid cysts[J]. Reprod Biomed Online, 2019, 38(6): 857-869.
[27] Zhu H, Cao X.NLR members in inflammation-associated carcinogenesis[J]. Cell Mol Immunol, 2017, 14(5): 403-405.
[28] Uchimura T, Oyama Y, Deng M, et al.The Innate Immune Sensor NLRC3 Acts as a Rheostat that Fine-Tunes T Cell Responses in Infection and Autoimmunity[J]. Immunity, 2018, 49(6): 1049-1061.
[29] Conti BJ, Davis BK, Zhang J, et al.CATERPILLER 16.2 (CLR16.2),a novel NBD/LRR family member that negatively regulates T cell function[J]. J Biol Chem, 2005, 280(18): 18375-18385.
[30] Li ZT, Liu H, Zhang WQ.NLRC3 alleviates hypoxia/reoxygenation induced inflammation in RAW264.7 cells by inhibiting K63-linked ubiquitination of TRAF6[J]. Hepatobiliary Pancreat Dis Int, 2020, 19(5): 455-460.
[31] Hu S, Du X, Huang Y, et al.NLRC3 negatively regulates CD4+ T cells and impacts protective immunity during Mycobacterium tuberculosis infection[J]. PLoS Pathog, 2018, 14(8): e1007266.
[32] Fu Y, Zhan X, Wang Y, et al.NLRC3 expression in dendritic cells attenuates CD4+ T cell response and autoimmunity[J]. EMBO J, 2019, 38(16): e101397.
[33] Kang JH, Li MJ, Luan PP, et al.NLRC3 silencing accelerates the invasion of hepatocellular carcinoma cell via IL-6/JAK2/STAT3 pathway activation[J]. Cell Biol Int, 2020, 44(10): 2053-2064.
[34] Karki R, Man SM, Malireddi RKS, et al.NLRC3 is an inhibitory sensor of PI3K-mTOR pathways in cancer[J]. Nature, 2016, 540(7634): 583-587.
[35] 尹保娜,薛文玲,毛晓红,等. 核苷酸结合寡聚化结构域样受体蛋白3在子宫内膜癌组织中的表达及与患者临床特征和预后的关系[J]. 癌症进展,2021,19(22):2307-2332.
[36] Chang MX, Xiong F, Wu XM, et al.The expanding and function of NLRC3 or NLRC3-like in teleost fish: Recent advances and novel insights[J]. Dev Comp Immunol, 2021, 114: 103859.
[37] Schneider M, Zimmermann AG, Roberts RA, et al.The innate immune sensor NLRC3 attenuates Toll-like receptor signaling via modification of the signaling adaptor TRAF6 and transcription factor NF-κB[J]. Nat Immunol, 2012, 13(9): 823-831.
[38] Li X, Deng M, Petrucelli AS, et al.Viral DNA Binding to NLRC3, an Inhibitory Nucleic Acid Sensor, Unleashes STING, a Cyclic Dinucleotide Receptor that Activates Type I Interferon[J]. Immunity, 2019, 50(3): 591-599.
[39] González-Ramos R, Defrère S, Devoto L.Nuclear factor-kappaB: a main regulator of inflammation and cell survival in endometriosis pathophysiology[J]. Fertil Steril, 2012, 98(3): 520-528.
[40] Qu H, Li L, Wang TL, et al.Epithelial Cells in Endometriosis and Adenomyosis Upregulate STING Expression[J]. Reprod Sci, 2020, 27(6): 1276-1284.
[41] Madanes D, Bilotas MA, Bastón JI, et al.PI3K/AKT pathway is altered in the endometriosis patient's endometrium and presents differences according to severity stage[J]. Gynecol Endocrinol, 2020, 36(5): 436-440.
[42] Kacan T, Yildiz C, Baloglu KS, et al.Everolimus as an mTOR Inhibitor Suppresses Endometriotic Implants:an Experimental Rat Study[J]. Geburtshilfe Frauenheilkd, 2017, 77(1): 66-72. |
